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Epidemiology and Immunogenetic 
Background of Islet Cell Antibody-
Positive Nondiabetic Schoolchildren 
Ulm-Frankfurt Population Study 
BERNHARD 0. BOEHM, BURKHARD MANFRAS, JOCHEN SEIßLER, KARL SCHÖFFLING, MICHAEL 
GLÜCK, GERHARD HOLZBERGER, SIEGFRIED SEIDL, PETER KÜHNL, MASSIMO TRUCCO, AND 
WERNER A. SCHERBAUM 
Islet cell ant ibodies (ICAs) were determined in a large 
cohort of whi te nondiabet ic schoolch i ldren (n = 4287) 
f rom a homogenous populat ion in southern Germany. 
The prevalence of ICA levels >5 Juveni le Diabetes 
Foundation (JDF) U was 1.05% (95% conf idence 
interval 0.8-1.4%). Analys is of HLA-DRß and -DQß 
alleles revealed that the specif ic i t ies found to be 
increased in insul in-dependent (type I) diabetic 
subjects wi th the same ethnic background were also 
associated wi th ICA posi t iv i ty in the nondiabet ic 
schoolchi ldren. HLA-DR3 (P < 0.01) and -DR4 (P < 
0.01) phenotypes and absence of Asp residue (P < 
0.01) at codon 57 of the HLA-DQ ß-chain were 
signif icantly increased in ICA+ compared wi th contro l 
subjects. High levels of ICAs, wh ich were categorized 
as either >17 or >30 JDF U, were found to be 
associated wi th amino acids other than Asp at posi t ion 
57 of the HLA-DQ ß-chain. No associat ion of ICA level 
was found for HLA-DR phenotypes. Diabetes 40:1435-
39, 1991 
Islet cell antibodies (ICAs) are recognized as a major se-rological hallmark of insulin-dependent (type I) diabetes mellitus and prediabetic insulitis (1,2). Most of our knowl-edge on the natural course of prediabetic insulitis and 
type I diabetes is derived from studies of nondiabetic rela-
tives of patients with type I diabetes (1,2). Therefore, a critical 
gap exists in our knowledge of the epidemiology of ICAs 
From the University Hospital of Frankfurt Medical School, Department of Gen-
eral Medicine, Endocrinology Section, and the Institute of Immunohematology, 
Frankfurt; the University Hospital of Ulm Medical School, Department of Gen-
eral Medicine, Ulm; the University Hospital of Hamburg Medical School, De-
partment of Immunohematology. Hamburg, Germany; and the University of 
Pittsburgh, School of Medicine, Department of Pediatrics, Children's Hospital, 
Pittsburgh, Pennsylvania. 
Address correspondence and reprint requests to Bernhard O. Boehm, MD, 
University Hospital of Frankfurt Medical School, Department of General Med-
icine, Laboratory of Molecular Immunology, 7 Theodor-Stern-Kai, W-6000 
Frankfurt 70, Germany. 
Received for publication 5 November 1990 and accepted in revised form 
12 June 1991. 
and their corresponding risk factors in the general population 
(3). Thus far, only six population-based studies, from Japan, 
Spain, Netherlands, Italy, Finland, and the United States, 
have partly addressed this issue, each of them providing 
limited or no data on the correlation with risk factors (see 
ref. 3 for review). 
Population and family studies suggest that type I diabetes 
develops on a particular genetic background that has been 
mapped to the major histocompatibility complex (MHC) (4). 
More than 95% of white type I diabetic subjects studied type 
as HLA-DR3 and/or -DR4. These alleles account for most of 
the immunogenetic background of the disease (4,5). Todd 
et al. (6) demonstrated that particular alleles at the HLA-
DQB1 locus are more closely associated with susceptibility 
than other HLA-DRB1 alleles. As confirmed in further studies, 
genetic resistance to the disease in whites is correlated with 
the presence of Asp at amino acid position 57 of the HLA-
DQ ß-chain (7). In a case-control study, "dominant protec-
t ion" was found with the HLA-DQw1.2 allele (Asp 5 7 DQß al-
lele) (8). Morel et al. (7) and Baisch et al. (8) also postulated 
that susceptibility is associated with all other amino acids 
(non-Asp) at codon 57, and "dominant susceptibility" was 
ascribed to the DQw8 allele (non-Asp). The molecular typing 
of the HLA-DQB1 chain provides a reliable molecular marker 
for type I diabetes, which in whites is superior to HLA-DR 
specificities. 
We studied a large group of schoolchildren in a homo-
genous German population to establish the prevalences of 
ICA positivity. We provided age-related prevalances for 
ICAs. Immunogenetic risk markers were also analyzed. HLA-
DR phenotypes were determined by HLA serology, and HLA-
DQß alleles were characterized by DNA typing. The aim of 
our study was to determine whether diabetogenic HLA risk 
factors are also associated with ICA positivity in the general 
population. 
RESEARCH DESIGN AND METHODS 
In a cross-sectional study between June 1988 and June 
1989, 4287 schoolchildren from a homogenous white pop-
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ulation in southern Germany (Alb-Donau County) were sur-
veyed to determine ICAs. The total population of school-
children in Alb-Donau County was 8031 (3730 boys, 4301 
girls). The average age was 13.9 yr with an effective range 
between 6 and 21 yr. No diabetic individuals took part in the 
study. 
This study was performed in accordance with the princi-
ples of the Declaration of Helsinki. Written consent was given 
by the local ethical committee, the data protection council, 
individuals >18 yr of age, and the parents of the children 
studied. A letter describing the aim of the study was sent to 
all schools in Alb-Donau County. An appointment with teach-
ers, parents, schoolchildren, and representatives of local 
newspapers was made, and the study protocol was dis-
cussed and drafted. All schools of Alb-Donau County 
showed a positive response, and 4287 of 8031 individuals 
volunteered for the study. 
ICA test ing. ICAs were determined by indirect immuno-
fluorescence testing on unfixed cryostat sections of human 
pancreas (9,10). The lower limit of detection in our assay 
was 5 Juvenile Diabetes Foundation (JDF) U. In an inter-
national quality-control workshop (JDF ICA Workshop), our 
laboratory achieved values of 100% for consistency, spec-
ificity, sensitivity, and validity (2nd Juvenile Diabetes Foun-
dation Workshop ICA Proficiency Program; laboratory no. 
116). ICA tests were read in a blinded fashion by two in-
dependent observers (M.G. and J.S.), and the results were 
transferred to JDF units with the standard curve of the pro-
gram mentioned above. 
HLA serological typ ing. The HLA-DR phenotypes were de-
termined by a two-color fluorescence technique according 
to van Rood et al. (11). Eight hundred eight randomly se-
lected nondiabetic individuals from the same geographic 
area, 185 type I patients as disease control subjects and 36 
ICA" individuals were typed from June 1988 to June 1989. 
All individuals studied shared the same ethnic background. 
As an internal control of the HLA-typing procedure, 16 ICA + 
individuals, 30 ICA control subjects, and 45 type I diabetic 
patients were typed twice. Samples were coded and the 
typing trays read in a blinded way by G.H., S.S., and P.K. 
The results of the two typings were identical. 
HLA DNA typ ing . Purified genomic DNA (0.5-1 |xg) isolated 
from peripheral blood leukocytes was subjected to 25 -30 
cycles of in vitro polymerase chain reaction amplification 
with the thermostable Taq polymerase (AmpliTaq, Perkin-
Elmer/Cetus, Emeryville, CA) in a programmable thermal 
cycler (Perkin-Elmer/Cetus) (12). The two HLA-DQB1-spe-
cific primers used (5'-GATTTCGTGTACCAGTTTAAGG-3' 
and 5'-GCAGACACAACTACGAGGTGG-3') recognized the 
beginning and the end of the second exon that encodes the 
first domain of the HLA-DQ ß-chain. The amplified material 
was dot-blotted on Nytran-filters (Schleicher and Schüll, 
Braunschweig, Germany) and was then probed with a panel 
of T4 kinase radiolabeled sequence-specific probes with 
stringent conditions that allowed the discrimination of even 
single nucleotide mismatches (7). A panel of nine oligonu-
cleotides was used to define eight HLA-DQB1 alleles. The 
filters were prehybridized at 42°C for 6 h and then probed 
at 42°C overnight with the oligonucleotides. The filters were 
washed six times in SSC (1 x SSC = 0.15 M NaCI/0.0015 
M sodium ci trate)/0.1% sodium dodecyl sulfate at a tem-
perature based on Td [4(number of GC base pairs) + 
2(number of AT base pairs)]. The appropriate temperatures 
required to wash off mismatched probes were 65°C for 
DQw3.2 (corresponding to amino acids [AA]54-59), 66°C 
for DQw3.1 (AA 54-59) , 52°C for DQw3.1-26 (AA 23-29) , 
62°C for DQw1.1 (AA 54-59) , 62°C for DQw1.9 (AA 54-59) 
and DQw2 (AA 52-58) , and 60°C for DQwLAZH (AA 5 4 -
59) and DQBIank (54-59). 
HLA data are given as allele frequencies and relative risk 
for the disease (13). The x 2 test was used to estimate sta-
tistical significance. P = 0.05 was used as the threshold for 
significance. Confidence intervals (CIs) were calculated with 
Poisson distribution. 
RESULTS 
Prevalence of ICAs. Forty-four (25 boys, 19 girls) of 4287 
individuals were ICA^ with an ICA level > 5 JDF U (Table 1). 
An overall prevalence of 1.05% (95% CI 0.8-1.4%) of ICA 
positivity was observed. None of these ICA • individuals had 
a family history of type I diabetes. Age-specific rates were 
calculated for the prevalence of ICAs. Children ranging in 
age from 7 to 17 yr revealed the highest prevalence of ICA 
positivity. A clustering of ICA positivity between the ages of 
12 and 15 yr was observed in boys (Table 1). Table 2 gives 
prevalence rates per 100 and 95% CI for ICA + subjects. 
HLA-DR phenotyp ing. Thirty-six ICA~ individuals (36 of 44, 
82%), 808 local nondiabetic control subjects, and 185 type 
I diabetic patients (disease controls) were serologically 
typed for HLA-DR (Table 3). The phenotypic frequencies of 
the HLA-DR3 and -DR4 alleles were significantly increased 
in ICA 1 schoolchildren compared with these control sub-
jects. Relative risks for ICA positivity were 3.4 (P < 0.01) 
and 3.6 (P < 0.001), respectively. HLA-DR7 was significantly 
reduced (P < 0.05) in ICA' schoolchildren compared with 
control subjects. A comparison of ICA' with type I diabetic 
TABLE 1 
Islet cell antibody-posit ive ( ICA r ) subjects in study population 
according to age 
Female Male 
Tested Tested 
Age (yr) n % ICA' n % ICA' 
6 46 45 0 28 46 0 
7 74 47 2 (2.7) 67 47 0 
8 94 55 1 (1.0) 81 59 1 (1.2) 
9 70 52 0 114 51 1 (0.9) 
10 128 58 2(1 .6) 116 57 0 
11 254 54 2 (0.8) 222 54 1 (0.5) 
12 243 55 2 (0.8) 278 54 5(1 .8 ) 
13 287 56 2 (0.7) 248 55 5 (2.0) 
14 228 57 3(1-3) 336 64 5(1 .5 ) 
15 238 56 2 (0.8) 171 54 1 (0.6) 
16 236 54 2 (0.8) 121 55 3 (2.5) 
17 173 50 0 102 55 3 (2.9) 
18 108 46 0 80 46 0 
19 54 47 1 (18) 34 37 0 
20 22 30 0 7 17 0 
21 25 42 0 2 15 0 
Total 2280 53 19 (0.8) 2007 54 25 (1.2) 
Percentage ICA* in parentheses. 
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TABLE 2 
Prevalence rates of islet cell antibody (ICA) positivity 
Age (yr) 
7 -9 10-12 13-15 16-18 19-21 Total 
Prevalence per 
100 subjects 1.22 1.22 1.23 0.95 0.21 1.05 
95% confidence interval 0.33-3.1 0.6-2.2 0.7-1.9 0.5-1.7 0.01-1.2 0.8-1.4 
patients revealed a similar distribution of DQB1 phenotypes 
with no statistical significant differences. 
HLA DNA typ ing . Data from HLA-DQB1 typing were sum-
marized in Tables 4 and 5. HLA-DQB1 alleles were deter-
mined in 31 schoolchildren, 104 type I diabetic subjects, 
and 123 healthy control subjects. Twenty (64.5%) of the ICA + 
patients were non-Asp homozygous or non-Asp/Blank. Of 
the ICA* schoolchildren, 93.5% had a non-Asp" HLA hap-
lotype. In contrast, a non-Asp haplotype was found in 71.5% 
of the local control subjects (P < 0.01). The results from the 
type I diabetic subjects and the control subjects compare 
well with the published data from Morel et al. (7) and Baisch 
et al. (8). When ICA + subjects were compared with the type 
I diabetic subjects, the number of non-Asp homozygous in-
dividuals was significantly increased in the latter group 
(P < 0.02). 
ICA levels and HLA. The association of ICA level and HLA 
types is summarized in Table 6. No association of a high 
ICA level >17 or >30 JDF U with HLA-DR3 and/or HLA-DR4 
was observed. When HLA-DQß alleles and ICA levels were 
compared, a clustering of high-level ICAs was observed in 
non-Asp + individuals. Fifty percent of the non-Asp + nondi-
abetic schoolchildren had ICA levels >30 JDF U compared 
with only 27% in A s p + individuals (Table 6). 
DISCUSSION 
This study shows that the presence of ICAs in a random 
population of whites 6-21 yr of age is associated with HLA-
DRß alleles and the absence of Asp at codon 57 of the HLA-
DQ ß-chain. This indicates that particular HLA-DQB1 alleles 
are not only genetic markers of type I diabetes (4,5), but 
they are also associated with an ongoing autoimmune pro-
cess reflected by circulating ICAs. Only 2 of 31 (6.5%) ICA + 
nondiabetic individuals compared to 47 (38.2%) control sub-
jects were homozygous for Asp at position 57 of the HLA-
DQ ß-chain. The highest prevalence of non-Asp homozy-
gotes was found in type I diabetic subjects. This genotype 
was significantly more frequent compared with control sub-
jects and ICA + patients. Non-Asp homozygosity was de-
scribed by Todd et al. (6) and Morel et al. (7) as the principle 
disease risk genotype in whites. Although this suggests that 
the immunogenetic background of our ICA" healthy children 
is not completely congruent with the high-risk HLA-markers 
found in type I diabetic subjects, the design of the study 
excluded ICA+ non-Asp homozygous subjects if they were 
already diabetic. In this way, the healthy ICA 4 population 
may be slightly enriched with those ICA + individuals that will 
not develop diabetes. 
Our study is the first that analyzed the association of poly-
morphisms at position 57 of the HLA-DQ ß-chain and ICA 
positivity. Six studies of different ethnic groups have ex-
amined the population prevalence of ICAs. Notsu et al. (14) 
reported a prevalence of 0.5% in 1242 rural Japanese vil-
lagers, Betterle et al. (15) found a 0.5% prevalence in 611 
adults, and Riley et al. (16) observed 0.4% in 2500 control 
subjects. Later, Maclaren et al. (17) reported a 0.84% ICA 
positivity in 5003 healthy Florida schoolchildren. From Spain, 
Bergeau et al. (18) reported a prevalence of 0.35% in 2291 
healthy teenagers, and Bruining et al. (19) reported 0.24% 
ICA + subjects from a group of 2805 Dutch children. In a 
report from Finland, 4.1 % of 1212 children and young adults 
were ICA + (20). The prevalence of ICA positivity in our group 
was 1.05% with a CI of 0.8-1.4% and was comparable with 
the results of Maclaren et al. Until now, the only analysis of 
HLA markers in ICA + healthy children came from the Florida 
study (17). A significant increase of HLA phenotypes that 
TABLE 3 
Phenotypic frequencies of HLA-DR specificities in islet cell antibody-posit ive ( ICA") individuals, control subjects, and 
insulin-dependent (type I) diabetic subjects 
ICA + (n = 36) Control (n = 808) Type I {n = 185) 
Frequency Relative Frequency Frequency 
n (%) Risk n (%) n (%) 
DR1 6 16.6* 
DR2 5 13.8* 
DR3 16 44.4* 3.4 
DR4 19 52.7§ 3.6 
DR5 7 19.4* 
DR6 7 19.4* 
DR7 3 8.3|| 0.3 
DR8 2 5.5* 
150 18.5 39 21.1t 
222 27.3 13 7.Of 
153 18.8 95 51.3t 
192 23.6 125 67.6f 
196 24.1 20 10.8f 
164 20.2 22 11.9f 
179 22.0 16 8.6t 
48 5.9 9 4.9f 
*NS, $P < 0.001, §P < 0.0001, ||P < 0.05, vs. control. 
f N S vs. ICA" individuals. 
HI ADCTCQ \ / m An N i n V / P M R P R 1QQ1 1437 
IMMUNOGENETICS OF ICA SCHOOLCHILDREN 
TABLE 4 
HLA-DR serology, HLA-DQB1 alleles, codon 57, and islet cell antibody (ICA) levels in ICA^ schoolchildren 
No. Code Gender/age (yr) HLA-DRB1 HLA-DQB1 Codon 57 (DQ ß-chain) ICA level (JDF U) 
1 8722012 M/17 3,- 2,3.1 NA/AA 90 
2 8723913 M/13 3,11 2,3.1 NA/AA 9 
3 8722050 F/15 4,6 3.2,1.2 NA/AA 17 
4 8721415 F/19 2,2 1.1,1.1 NA/NA 30 
5 8722062 F/15 1,2 1.2,1.2 AA/AA 17 
6 8721733 M/14 6,11 1.2,1.2 AA/AA 9 
7 8723944 M/13 3.4 2,3.1 NA/AA 17 
8 8724196 M/12 4,7 3.1,2 AA/NA 9 
9 9905031 M/14 1,2 1.1.1.AZH NA/NA 54 
10 8722436 F/11 4,11 3.2,1.1 NA/NA 5 
11 9904972 F/07 3,6 2,- NA/- 9 
12 9904944 M/09 7,11 ND ND 17 
13 9905374 M/17 3,6 2,1.2 NA/AA 54 
14 8722424 M/12 4,8 3.2,3.2 NA/NA 90 
15 8722564 F/07 1,3 1.1,2 NA/NA 30 
16 8721790 F/10 4,12 3.2,2 NA/NA 160 
17 9904913 F/10 2,4 ND ND 54 
18 8723957 M/14 4,6 3.2,1.1 NA/NA 54 
19 8724646 M/13 3,4 2,3.2 NA/NA 9 
20 8722021 M/16 1,2 1.1,1.2 NA/AA 17 
21 8723896 F/11 3,4 2,3.1 NA/AA 5 
22 8723637 M/11 4,11 3.2,1.2 NA/AA 90 
23 8722221 F/08 4,6 3.2,1,1 NA/NA 30 
24 8724230 F/14 4,4 ND ND 5 
25 8724249 F/12 3,3 2,2 NA/NA 17 
26 8721879 M/12 3,4 2,3.2 NA/NA 5 
27 8726445 M/16 ND ND ND 9 
28 8726605 F/14 3,- 2,- NA/- 5 
29 8722017 M/16 ND 1.1,1,1 NA/NA 30 
30 8721398 F/16 1,3 1.1,2 NA/NA 90 
31 9905184 M/17 3,- 2.2 NA/NA 17 
32 9905277 F/16 ND ND ND 5 
33 8721739 F/14 6,8 ND ND 90 
34 8723964 F/13 ND ND ND 17 
35 8724882 F/13 3,4 2,3.2 NA/NA 90 
36 8722263 M/08 ND ND ND 30 
37 8727076 M/15 3,4 2,- NA,- 90 
38 8724239 M/13 ND ND ND 9 
39 8724860 M/12 3,4 2.- NA,- 9 
40 8722179 M/14 4,- 3.2,3.2 NA/NA 9 
41 8722482 M/13 ND ND ND 17 
42 8724168 M/12 ND ND ND 9 
43 8726644 M/14 1,7 ND ND 9 
44 8722414 F/12 4,11 ND ND 9 
JDF, Juvenile Diabetes Foundation; NA, amino acid other than aspartic acid at position 57 of the HLA-DQ ß-chain; AA, aspartic acid at 
codon 57 of the HLA-DQ ß-chain; ND, not determined; -, Blank. 
included HLA-DR3 and/or -DR4 alleles was found when the 
comparison was made to healthy control subjects. This inital 
observation has recently been extended (21). In 31 of 49 
ICA 4 individuals, HLA-DR phenotypes were analyzed (20 
subjects [64%] were DR4 f and 21 subjects [67%] were 
DR3 + ) . The significant increase of these DR phenotypes 
compared with the control subjects was shared by the 
schoolchildren from Florida and our cohort of whites. 
ICAs and genetic risk markers have been extensively stud-
ied in relatives of patients with type I diabetes (3). Family 
TABLE 5 
Relationship of presence or absence of aspartic acid to islet cell antibody (ICA) positivity 
Haplotype at position 57 Controls {n = 123) ICA' (n = 31) Type 1 (n = 104) 
Asp/Asp or Asp/Blank 35 (28.4) 2 (6.5)* 0 ( 0 ) 
Asp/non-Asp 47 (38.2) 9 (29.0) t * 16(15.4)§ 
Non-Asp/non-Asp or non-Asp/Blank 41 (33.4) 20 (64 .5) | 88 (84.6)§ 
Any haplotype including 1 non-Asp allele 88 (71.5) 29 (93.5)*} 100 (100)§ 
Values in parentheses are percentages. Statistical analysis was performed within the control group, insulin-dependent (type I) diabetic 
patients, and ICA f individuals. 
*NS,§P < 0.02, vs. type I diabetic patients. 
tNS , $P < 0.01, vs. control group. 
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TABLE 6 
Islet cell antibody (ICA) levels and HLA-DRB1 and HLA-DQB1 alleles 
non-Asp/Asp or non-Asp/- or non-Asp/ 
ICA level DR4 ' (n = 19) DRX* (n = 16) DR3 + (n = 16) DRXf {n — 19) Asp/Asp (n = 11) non-Asp (n = 20) 
^ 1 7 J D F U 10 (53) 12(75) 9 (56) 13 (68) 6 (55) 13 (65) 
> 3 0 JDF U 8 (42) 7 (44) 6 (37 ) 9 (47 ) 3 (27 ) 10 (50) 
Values in parentheses are percentages. JDF, Juvenile Diabetes Foundation; -, Blank. 
'Denotes any HLA-DR phenotype other than HLA-DR4. 
^Denotes any HLA-DR phenotype other than HLA-DR3. 
studies have shown that most first-degree relatives who be-
came diabetic had ICAs detectable before diagnosis (1,2). 
However, only a portion of ICA + individuals will develop the 
disease later on. ICAs can even occur in identical twins with 
only one of them developing type I diabetes (22). In this 
context, note that high levels of ICAs were described to be 
of high predictive value for future type I diabetes (1,2,23). 
Recently, Riley et al. (23) observed in a prospective study 
in relatives of type I patients that ICA levels >20 JDF U were 
associated with an increasing risk of the development of 
diabetes. High levels of ICAs, i.e., >17 or >30 JDF U were 
found more often in our population survey in non-Asp pos-
itives. Individuals with an Asp" HLA haplotype had lower 
levels of ICAs. No association between particular HLA-DR 
phenotypes and high levels of ICAs could be detected in 
this study. This may indicate that the immune response to 
islet cell antigen, as reflected by the level of ICAs, is more 
strongly associated with HLA-DQB1 alleles compared with 
the HLA-DRß phenotypes. 
After a follow-up of 976 proband yr, one individual in our 
cohort (no. 9905031) developed diabetes. This individual 
was DNA typed as non-Asp homozygous and revealed high 
levels of ICAs during the initial survey in 1988. We demon-
strated that HLA-DR and -DQ alleles found in type I diabetic 
subjects were also associated with ICA positivity in a random 
population. We plan to follow the well-characterized popu-
lation of ICA" nondiabetic individuals described in this report 
to determine whether the combination of ICA testing and 
DQß determination will be a better predictor for type I dia-
betes susceptibility. 
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